Gilead Sciences Denmark Aps

Gammel Kongevej 60 

1850 Frederiksberg C 



Medical Information: 

Adverse Events: 

Product Complaints:


Nordic Regional Office

Gilead Sciences Sweden AB

Solna Gate

Hemvärnsgatan 9

171 54 Solna


Phone: +46 8 505 718 00 +46 8 505 718 00

Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Grants to HCOs registered in Denmark

Description Recipient Type of grant Purpose Timeframe Amount funded DKK Extent, content and estimated value of the benefit in kind
HIV Comorbidity Screening Project Department of Infectious Diseases 8632
Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
Project Grant Rigshospitalet will screen patients with HIV aged 60 years and above for comorbidities and lifestyle-connected diseases. August 2022 – August 2023 500.000DKK (excl. VAT) Patient educational material
Perform a nationwide, population-based, cross-sectional register study of the entire adult Danish population, estimating the prevalence pf blood-borne viruses and risk factors among people with severe mental illness (SMI) Department of Infectious Diseases, Aarhus University Hospital, Denmark Research Grant To estimate the point prevalence of HIV, HBV and HCV infection among people with SMI. January 1, 2022 – December 31, 2023 315,000 DKK (excluding VAT) N/A
Becoming and being a mother living with HIV – a multicenter longitudinal mixed methods study Amager & Hvidovre Hospital, Dep. of Infectious Diseases, Copenhagen Univ. Hospital Research Grant Research study to investigate psychosocial outcomes and experiences of women living with HIV during pregnancy and early motherhood Date; Jan 2021 – Dec 2022 427 500 DKK N/A
Pathobiology guided therapy in immune-mediated inflammatory arthritis: study using ex vivo models Aarhus University Hospital, Department of Biomedicine, Health Research Grant Research to provide novel insights into the molecular heterogeneity of immune-medicated arthritis and possibly identify markers for less impersonal treatment strategies Date: Jan 2021 – Dec 2022 250 000 DKK N/A
Updated estimate of hepatitis B and C prevalence Odense University Hospital, Department of Infectious diseases Research Grant Estimate prevalence of HCV and HBV in DK Date: Jan 2021 – Dec 2022 70 000 DKK N/A
To offer testing to all users of the Substance Abuse Center to identify those with hepatitis C Regionshospitalet Viborg, Medicinsk Afdeling, Klinik for Infektionssygdomme Heibergs Allé 2K 8800 Viborg, Denmark. Research Grant Testing for hepatitis C at a place where people who use drugs receive services. Grant covers salary for medical laboratory technologist and nurse. August 1, 2021 – June 30, 2023 37,800 DKK –VAT excluded N/A
This nationwide, multi-center survey study aims to investigate psychosocial, sexual and reproductive health among people living with HIV in Denmark, compared to people not living with HIV. Faculty of Health and Medical Sciences, University of Copenhagen, Denmark Research Grant To investigate psychosocial, sexual and reproductive health among people living with HIV in Denmark, compared to people not living with HIV. Jan. 1 2022 – Feb. 28 2023 720,000 DKK N/A
This nationwide cohort study will compare B-cell lymphoma patient trajectories and survival between immigrants and the host population. Department of Hematology, Aalborg, Denmark. Research Grant To explore the differences in patient trajectories for immigrants compared to the host population and to detect at which point in the trajectories the differences occur. Jan. 1 2022 – Dec. 31, 2022 317,500 DKK N/A
This study will investigate if myocardial dysfunction assessed using echocardiography and NT-proBNP (biomarker of cardiac function used in heart failure) is more prevalent in people living with HIV compared with controls. Echocardiography has been performed and NT-proBNP will be measured from biobank samples. Rigshospitalet Copenhagen, Denmark Research Grant To compare prevalence of asymptomatic cardiac dysfunction assessed using echocardiography and NT-proBNP in a large cohort of people living with HIV and uninfected controls from the general population and determine if HIV infection is an independent risk factor for asymptomatic cardiac dysfunction. Jan. 1 2022 – Dec. 1, 2023 300,000 DKK N/A
To analyze the long-term prognosis of HIV-TB co-infected patients within the TB: HIV Study, based on 8-10 years of follow-up. To compare long-term survival and causes of death across groups of people living with HIV, including those with and without TB. Department of Infectious Diseases, Copenhagen University Hospital, Denmark Research Grant To analyze the long-term prognosis, survival and causes of death of HIV-TB co-infected patients Jan. 1 2022 – Dec. 31, 2022 325,180 DKK (excluding VAT). N/A

Relationships with Patient Organizations

Gilead provided support to the following patient organization from Denmark in 2021. The information is correct at the time of writing (October 2021). The information is subject to change and periodic updates. For a listing of previous years’ payments, click here.

Recipient Description of activity Amount funded DKK
Brugernes Akademi – Dannebrogsgade, 1660 København, Denmark

Contact: Jannet van der Veen
Produce a podcast series of at least 5 episodes.

The podcast’s main topic is the challenges the Users Academy meets in finding and treating people infected with HCV.
30,000.00 DKK (excluding VAT)
Patientforeningen Hiv-Danmark

Contact: Kicki Mikkelsen
An educational seminar to be held on September 2022 in cooperation with the Infectious Disease Department at Rigshospitalet, Copenhagen, intended for the Danish HIV-community, HIV-volunteers and health care professionals connected to HIV outpatients’ clinics in greater Copenhagen area. 22,318 DKK
(3000 EURO)
This page is intended for visitors outside of the United States.